Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
Clinical trial NCT07231250 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07231250
- Sponsor
- Li Zhiming
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-01-15
- Primary completion
- 2026-09-15
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.